At present, clinical staff shows a strong interest in ligands for LXRS and PPARs for the treatment of cardiovascular disease, and they are ligand-activated transcription factors that plays well-established roles in up-regulating transcription of ABCA1 and ABCG1 [27,28]. Here, ABCG1 is linked to cardiovascular disorder.